PITTSBURGH, April 12, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) plans to report its first quarter 2023 financial results on Monday, May 8 before the open of the U.S. financial markets. Chief Executive Officer Scott Smith, President Rajiv Malik, and Chief Financial Officer Sanjeev Narula also will host a webcast at 8:30 a.m. ET on May 8 to discuss the results.
Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 800-579-2543 or 785-424-1789 for international callers (Conference ID: VTRSQ123). A replay of the webcast also will be available on the website.
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical, and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines and a variety of over-the-counter consumer products. With approximately 37,000 colleagues globally, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn, Instagram and YouTube.
Last Trade: | US$11.96 |
Daily Change: | -0.04 -0.33 |
Daily Volume: | 4,972,020 |
Market Cap: | US$14.230B |
December 18, 2024 November 07, 2024 October 16, 2024 October 09, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load